Du är här


FIT Biotech Oy: FIT Biotech to publish H1/2015 Interim Report on August 31st, 2015 at 9.00 EET

Company release August 14th, 2015 at 08.30 EET

FIT Biotech to publish H1/2015 Interim Report on August 31st, 2015 at 9.00 EET

Fit Biotech Oy will publish Interim Report from the period January 1st - June
30th, 2015 on Monday 31st of August, 2015 at 9.00 EET.

FIT Biotech will inform the publishing date of the Financial Statements for
2015 in connection of the H1/2015 Interim Report.


Additional information:
CEO Kalevi Reijonen, FIT Biotech Oy Email:kalevi.reijonen@fitbiotech.comPhone:
+358 40 843 5695

Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790

FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA
vaccines and gene therapy. The company bases its products on its patented GTU
® (Gene Transport Unit) technology. Through GTU technology, FIT Biotech
develops DNA vaccines in order to both prevent and also treat various
diseases. Identified application areas include HIV, tuberculosis (and other
infectious diseases) as well as gene therapy (cancer, autoimmune diseases).
Other application areas are under development. FIT Biotech Oy is listed on
NASDAQ First North (ticker: FITBIO). More information can be found

Principal media


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.